Hemab Therapeutics Holdings, Inc. (COAG)
41.45
+1.03
(+2.55%)
USD |
NASDAQ |
Oct 30, 16:00
41.45
0.00 (0.00%)
After-Hours: 20:00
Hemab Therapeutics Holdings Shareholders Equity (Quarterly) : 454.27M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 454.27M |
| Date | Value |
|---|---|
| March 31, 2026 | -198.62M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 467.78M |
| Total Liabilities (Quarterly) | 13.51M |
| Debt to Equity Ratio | 0.0023 |
| Current Ratio | 35.85 |
| Net Debt Paydown Yield | 1.74% |